Posted by med_empowered on October 21, 2005, at 5:43:17
In reply to Re: Triple reuptake inhibitors and MAOIs » SLS, posted by Chairman_MAO on October 21, 2005, at 0:18:18
It seems that, in treating depression, "abuse potential" is a big problem. Never mind that the Adderall and Ritalin we hand out like candy (at least in the US) can cause some serious problems and they're both schedule II substances; if an antidepressant has even a hint of abuse-potential, it gets black-balled. Look at amineptine. There were a few recorded cases of abuse, but they occured mostly in people with other problems--polydrug users, people with personality disorders, etc. And yet...amineptine has been pushed off the scene, leaving us with such fun drugs as Zoloft to take its place. It also seems like drug companies prefer to re-hash old drugs, make "new" combo drugs (ex: Symbyax), or make lots of "me-too" drugs instead of doing anything terribly innovative or helpful. And yet...we (especially in the US) are still expected to pay inflated drug prices for meds that are often pretty old, unoriginal, and only moderately effective, at best. Great system.
poster:med_empowered
thread:568913
URL: http://www.dr-bob.org/babble/20051017/msgs/569724.html